Recommendations updated for meningococcal vaccine in HIV

Recommendations updated for meningococcal vaccine in HIV

(HealthDay)—In the Nov. 4 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, new recommendations are presented for meningococcal conjugate vaccination among HIV-infected individuals.

Noting that a growing body of evidence suggests increased risk for meningococcal disease in HIV-infected individuals, Jessica R. MacNeil, M.P.H., from the CDC in Atlanta, and colleagues modified recommendations on vaccination with meningococcal conjugate vaccine.

The authors recommend that all HIV-infected individuals aged ≥2 months should receive meningococcal conjugate vaccine (serogroups A, C, W, and Y); a multi-dose schedule should be used for children aged younger than 2 years. A two-dose primary series of meningococcal conjugate vaccine is recommended for individuals aged ≥2 years. A booster dose should be given at the earliest opportunity (at least eight weeks after the previous dose) for persons with HIV who have been previously vaccinated; boosters should continue at appropriate intervals. A booster dose should be administered three years later if the most recent dose was received before age 7 years. If the most recent dose was received at age ≥7 years, a booster should be given five years later and every five years thereafter.

"The recommendations for children aged 2 months through 2 years and persons aged ≥25 years are based on expert opinion; the vaccine was not studied in HIV-infected persons in these age groups," the authors write.


Explore further

AAP updates recommendations for meningococcal vaccines

More information: Full Text

Copyright © 2016 HealthDay. All rights reserved.

Citation: Recommendations updated for meningococcal vaccine in HIV (2016, November 7) retrieved 22 November 2019 from https://medicalxpress.com/news/2016-11-meningococcal-vaccine-hiv.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
24 shares

Feedback to editors

User comments